Odyssey Therapeutics (ODTX) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($871.8 million vs $730.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ODTX | SLDB |
|---|---|---|
| Share price | $18.14 | $6.81 |
| Market cap | $871.78M | $730.20M |
| 1-day change | +0.33% | -0.58% |
| YTD return | — | +21.45% |
| 1-year return | — | +24.09% |
| 5-year return | — | -79.70% |
| EPS (TTM) | $-7.55 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.05 | $11.45 |
| 52-week low | $15.10 | $3.79 |
| Distance from 52-week high | -37.56% | -40.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +97.08% | +173.42% |
| Average volume | 270.92K | 1.09M |
| Shares outstanding | 48.06M | 107.23M |
| Employees | 100 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
ODTX vs SLDB FAQ
Which is bigger, Odyssey Therapeutics or Solid Biosciences?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $871.78M compared with $730.20M for Solid Biosciences (SLDB).
Are Odyssey Therapeutics and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.